Antharis Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Series A

  • Investors
  • 3

Antharis Therapeutics General Information

Description

Operator of a multinational biopharmaceutical company intended to develop new treatments for cancer and inflammatory diseases. The company utilizes next-generation therapeutic monoclonal antibodies and antibody-drug conjugates to treat unmet medical needs, enabling patients with serious illnesses to live healthy and long lives.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 6370 Nancy Ridge Drive
  • Suite 112
  • San Diego, CA 92121
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 6370 Nancy Ridge Drive
  • Suite 112
  • San Diego, CA 92121
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Antharis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 14-Jul-2022 Completed Pre-Clinical Trials
1. Seed Round 01-May-2020 Completed Stealth
To view Antharis Therapeutics’s complete valuation and funding history, request access »

Antharis Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view Antharis Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Antharis Therapeutics Patents

Antharis Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260115303-A1 Cdh17-binding antibodies and methods of use thereof Pending 25-Oct-2024
WO-2026090578-A1 Cdh17-binding antibodies and methods of use thereof Pending 25-Oct-2024
US-20260159608-A1 Flt3-binding antibodies and methods of use thereof Pending 25-Oct-2024
WO-2026090567-A1 Flt3-binding antibodies and methods of use thereof Pending 25-Oct-2024
US-20260035466-A1 Vista-binding antibodies and methods of use thereof Pending 01-Aug-2024 C07K16/2827
To view Antharis Therapeutics’s complete patent history, request access »

Antharis Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Antharis Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Yazbeck & Co. Venture Capital Minority
Fuse Capital (Private Equity) Venture Capital Minority
iBionext Accelerator/Incubator Minority
To view Antharis Therapeutics’s complete investors history, request access »

Antharis Therapeutics Acquisitions (2)

Antharis Therapeutics’s most recent deal was a Merger/Acquisition with Galileo Biotech. The deal was made on 23-Aug-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Galileo Biotech 23-Aug-2023 Merger/Acquisition Biotechnology
Cassyni Biopharma 14-Jul-2022 Merger/Acquisition Biotechnology
To view Antharis Therapeutics’s complete acquisitions history, request access »

Antharis Therapeutics Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Galileo Biotech Rio de Janeiro, Brazil 2015

Antharis Therapeutics FAQs

  • When was Antharis Therapeutics founded?

    Antharis Therapeutics was founded in 2020.

  • Where is Antharis Therapeutics headquartered?

    Antharis Therapeutics is headquartered in San Diego, CA.

  • What is the size of Antharis Therapeutics?

    Antharis Therapeutics has 17 total employees.

  • What industry is Antharis Therapeutics in?

    Antharis Therapeutics’s primary industry is Drug Discovery.

  • Is Antharis Therapeutics a private or public company?

    Antharis Therapeutics is a Private company.

  • What is the current valuation of Antharis Therapeutics?

    The current valuation of Antharis Therapeutics is .

  • What is Antharis Therapeutics’s current revenue?

    The current revenue for Antharis Therapeutics is .

  • How much funding has Antharis Therapeutics raised over time?

    Antharis Therapeutics has raised $5.2M.

  • Who are Antharis Therapeutics’s investors?

    Yazbeck & Co., Fuse Capital (Private Equity), and iBionext have invested in Antharis Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process